Results 111 to 120 of about 2,193 (158)

panTB-HM: a multi-arm clinical trial of a pan-TB regimen targeting both host and microbe. [PDF]

Trials
Mudzengi D, Mashatole S, Xiang Q, Adrion C, Glover N, Ngwanto T, Mdluli J, Boniface S, Rassool M, Matome B, Paramo L, Svensson E, Fasanmi A, Angelo S, Moyo M, Marx C, Khosa C, Mokaba L, Mofokeng N, Lalashowi J, Nacy C, Charalambous S, Fumane E, Maphossa V, Beattie T, Brumskine W, Venter C, Mapamba D, Heinrich N, Rajaram S, Kooverjee S, Botha L, Nell M, Easton A, Foraida S, Warren RM, Sabi I, Ntinginya N, Wallis RS, panTB-HM Consortium.   +39 more
europepmc   +1 more source

Research overview-2025: integrating scientific progress to accelerate global tuberculosis elimination. [PDF]

Front Tuberc
Moonan PK, Holtz TH.
europepmc   +1 more source

Impact of fluoroquinolone resistance on the cost-effectiveness of empiric treatment for multidrug- or rifampicin-resistant tuberculosis. [PDF]

PLOS Glob Public Health
Kim C, Sweeney S, Sohn H, Knight GM, McQuaid CF.   +4 more
europepmc   +1 more source

The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)-Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings-A Prospective Cohort Study in Belarus and Uzbekistan. [PDF]

Clin Infect Dis
Sinha A, Klebe R, Rekart ML, Alvarez JL, Skrahina A, Yatskevich N, Solodovnikova V, Viatushka D, Parpieva N, Safaev K, Liverko I, Tigay Z, Moe S, Khristusev A, Allamuratova S, Mirzabaev S, Achilov M, Samieva N, Lachenal N, Merle CS, Sall FB, Restrepo CG, Tan C, Sitali N, Saunders MJ.   +24 more
europepmc   +1 more source

Correction: Molecular resistance mechanisms to newly approved antibiotics (2017-2025) in WHO priority pathogens. [PDF]

Front Microbiol
Frontiers Production Office.
europepmc   +1 more source

The pharmacokinetics (PK) / pharmacodynamics (PD) of pretomanid, delamanid and bedaquiline in the BALB/c mouse model of central nervous system tuberculosis. [PDF]

BMC Infect Dis
Zhu H, Ye Y, Fu L, Zhang W, Wang B, Chen X, Lu Y.   +6 more
europepmc   +1 more source

A New Era in Tuberculosis Prevention and Treatment: Breakthroughs in Drug Development and Future Prospects. [PDF]

Infect Dis Ther
Zhao CY, Song C, Lu YB, Huang AC, Zeng CM, Liu RH, Li WW, Xie ZH, Zhu QD.   +8 more
europepmc   +1 more source

Current and emerging therapies for pulmonary tuberculosis in adults. [PDF]

BMJ Med
Mahmood A, Ashfaq MB, Drain C, Melby E, Hunter M, Shaw TD.   +5 more
europepmc   +1 more source

Relapse and Emergent Resistance With Novel Short-Course Regimens for Multidrug-Resistant Tuberculosis, United States, 2022-2024. [PDF]

Open Forum Infect Dis
Liang R, Brust JCM, Reed C, Escuyer V, Armstrong DT, Parrish N, Valois P, Rowlinson MC, Marinova-Petkova A, Bisson GP, Labuda SM, Colon-Semidey A, Haley CA, Ashkin D, Peloquin CA, Lardizabal A, Patrawalla A, Cuenca A, Haas MK, Brostrom R, Mbakwem C, Schechter MC, Ray SM, Cummins J, Cahill B, Arn K, Chen LL, Wilson JW, Goswami ND.   +28 more
europepmc   +1 more source

New drugs for the management of tuberculosis. [PDF]

Curr Opin Infect Dis
Cross GB.
europepmc   +1 more source